SEC recommends Bio E’s 14-valent pneumococcal conjugate vaccine PCV14 for infants https://ift.tt/JUV2tG3

The company said its PCV14 is comparable, in terms of serotype coverage for infants, to the two pneumococcal conjugate vaccines – Pfizer’s Prevnar13 and Merck’s VAXNEUVANCE -- that are currently approved globally.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/dxb8F0D
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Labels

Blog Archive

Recent Posts

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.